Reported Standalone quarterly numbers for Lincoln Pharmaceuticals are:Net Sales at Rs 133.77 crore in December 2022 up 11.58% from Rs. 119.88 crore in December 2021.
Quarterly Net Profit at Rs. 21.61 crore in December 2022 up 22.79% from Rs. 17.60 crore in December 2021.
EBITDA stands at Rs. 33.11 crore in December 2022 up 26.96% from Rs. 26.08 crore in December 2021.
Lincoln Pharma EPS has increased to Rs. 10.79 in December 2022 from Rs. 8.79 in December 2021.
| Lincoln Pharma shares closed at 329.80 on March 13, 2023 (NSE) and has given 9.17% returns over the last 6 months and 5.40% over the last 12 months. |
| Lincoln Pharmaceuticals | | Standalone Quarterly Results | in Rs. Cr. |
|
| Dec'22 | Sep'22 | Dec'21 | | Net Sales/Income from operations | 133.77 | 140.61 | 119.88 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 133.77 | 140.61 | 119.88 | | EXPENDITURE | | Consumption of Raw Materials | 47.74 | 51.51 | 40.04 | | Purchase of Traded Goods | 20.60 | 22.67 | 20.87 | | Increase/Decrease in Stocks | -4.42 | -6.59 | -5.09 | | Power & Fuel | -- | -- | -- | | Employees Cost | 23.44 | 23.03 | 17.07 | | Depreciation | 2.26 | 2.42 | 2.18 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 19.66 | 21.09 | 23.54 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 24.49 | 26.49 | 21.27 | | Other Income | 6.36 | 5.69 | 2.64 | | P/L Before Int., Excpt. Items & Tax | 30.85 | 32.17 | 23.90 | | Interest | 0.33 | 0.14 | 0.31 | | P/L Before Exceptional Items & Tax | 30.52 | 32.03 | 23.60 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 30.52 | 32.03 | 23.60 | | Tax | 8.90 | 8.32 | 6.00 | | P/L After Tax from Ordinary Activities | 21.61 | 23.71 | 17.60 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 21.61 | 23.71 | 17.60 | | Equity Share Capital | 20.03 | 20.03 | 20.03 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 10.79 | 11.84 | 8.79 | | Diluted EPS | 10.79 | 11.84 | 8.79 | | EPS After Extra Ordinary | | Basic EPS | 10.79 | 11.84 | 8.79 | | Diluted EPS | 10.79 | 11.84 | 8.79 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
